Meta-analysis of the impact on early and late mortality of TAVI compared to surgical aortic valve replacement in high and low-intermediate surgical risk patients by Sergi, Daniele et al.
5402
Abstract. – OBJECTIVE: We studied the im-
pact of transcatheter aortic valve implantation 
(TAVI) compared to the surgical aortic valve re-
placement (SAVR) on 30-day and one-year mor-
tality from randomized controlled trials (RCTs) 
in patients with severe aortic stenosis at high or 
low-intermediate surgical risk.
MATERIALS AND METHODS: All RCTs were 
retrieved through PubMed computerized data-
base and the site https://www.clinicaltrials.gov 
from January 2010 until March 31st, 2019. The 
absolute risk reduction (RD) with the 95% con-
fidence interval (CI) was used to assess the ef-
fectiveness of the intervention under compar-
ison. We evaluated overall mortality rates at 
30-day and one-year follow-up in the compari-
son between TAVI vs. SAVR. We also evaluated 
the role played by the site access for TAVI per-
formed through the femoral or subclavian ar-
tery (TV-TAVI) vs. SAVR, or transapically (TA-TA-
VI) vs. SAVR.
RESULTS: In the “as-treated population” the 
overall 30-day mortality was significantly low-
er in TAVI (p=0.03) with respect to SAVR. How-
ever, the analysis for TAVI subgroups showed 
that 30-day mortality was (1) significantly low-
er in TV-TAVI vs. SAVR (p=0.006), (2) increased, 
not significantly, in TA-TAVI vs. SAVR (p=0.62). 
No significant differences were found between 
TAVI vs. SAVR at one-year follow-up.
CONCLUSIONS: The results of our meta-anal-
ysis suggest that TV-TAVI is a powerful tool in 
the treatment of severe aortic stenosis at high 
or low-intermediate surgical risk, with a signif-
icant lower mortality with respect to SAVR. On 
the contrary, SAVR seems to provide better re-
sults than TA-TAVI.
Key Words:
Aortic stenosis, SAVR, Transcatheter aortic-valve re-
placement, Transcatheter aortic valve implantation, 
TAVI, TAVR.
Introduction
Surgical aortic valve replacement (SAVR) in 
the past was the gold standard treatment for 
severe symptomatic native aortic valve stenosis 
(AS) at high or intermediate surgical risk1. Since 
the first intervention in 2002, transcatheter aortic 
valve implantation (TAVI) is recognized as an 
effective therapy for treatment of AS in high, in-
termediate, and even low-risk operable patients2. 
Recent randomized trials of TAVR showed that, 
in patients who were at intermediate or high 
risk for death with surgery, TAVR was either 
superior or non-inferior to standard therapies, 
including SAVR3-13. These results led to new of 
ESC and AHA/ACC guidelines, that recommend: 
(1) TAVI among high-risk patients with severe, 
symptomatic AS (stage D), after consideration 
by a heart valve team, Class I (LOE A); (2) TA-
VI as a reasonable alternative to surgical AVR 
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for patients with severe, symptomatic AS (stage 
D) and intermediate surgical risk, after consid-
eration by a heart valve team (Class IIa, LOE 
B-R)14,15. However, in Europe 50% of TAVI are 
performed in patients at intermediate and 10% in 
low-surgical risk patients16. The site access route 
routinely used for TAVI is the transfemoral (TF) 
approach. However, transapical (TA), subclavian 
artery (TS), axillary artery (AX) and most re-
cently direct aortic (DA) access have developed 
when TF is precluded because of small vessel 
caliber and peripheral vascular disease17-19. The 
TF-TAVI is reported to be associated to minor 
incidence of adverse events than TA-TAVI and 
SAVR. In adjunct SAVR performs better than 
TA-TAVI20. Moreover, there is insufficient ev-
idence regarding the comparison of TAVI vs. 
SAVR in severe AS at low surgical risk21,22. In 
adjunct previous review and meta-analyses failed 
to formally rate either the quality of the evidence 
or the credibility of subgroup analyses or provide 
absolute risks20,23,24. This prompted us to update 
a meta-analysis of randomized controlled tri-
als (RCTs) on the impact of TAVI compared to 
SVAR in high and low-intermediate surgical risk 
patients to assess: (1) mortality at 30-day and at 
one-year of follow-up and (2) the influence of the 
site access for TAVI.
Materials and Methods
 
This review and meta-analysis was performed 
in accordance with the PRISMA (Preferred Re-
porting Items for Systematic Reviews and Me-
ta-Analyses) statement.
Search Strategy and Data Sources
A systematic literature search for “TAVI” or 
“TAVR” was performed through PubMed com-
puterized database and through the site https://
www.clinicaltrials.gov from January 2010 until 
March 31st, 2019. Additional manual search was 
performed consulting relevant systematic reviews 
to check the included trials. All RCTs designed 
for a direct comparison of TAVI vs. SVAR in pa-
tients with severe, symptomatic AS were includ-
ed. The access site for TAVI was also collected. 
TF-TAVI together to TS-TAVI and AX-TAVI 
were named transvascular TAVI (TV-TAVI). Two 
investigators independently selected and exam-
ined the trial design (superiority or non-inferior-
ity), site access and the method employed to an-
alyze the results. Discrepancy in data extraction 
was resolved in discussion with a third author, 
until consensus was achieved. The search was re-
stricted to English-language journals. Exclusion 
criteria were all studies performed without the 
random design allocation of patients to TAVI or 
SAVR treatments, observational studies, confer-
ence abstract and proceedings.
Data Analysis
The analysis was performed with the Review 
Manager [Computer program] Version 5.3. Co-
penhagen: The Nordic Cochrane Centre, the Co-
chrane Collaborations, 2014. The absolute risk 
reduction (RD) with the 95% confidence interval 
(CI) was used to assess the effectiveness of the 
intervention under study. 
The Forest plots were examined to detect 
homogeneity/heterogeneity among studies. Ho-
mogeneity/heterogeneity were quantified with 
the Cochran’s Q test and I2 statistics. The Man-
tel-Haenszel fixed effect model was adopted in-
stead of the random effect model in the absence 
of heterogeneity25. The primary endpoints were a 
composite of death from any cause at 30-day and 
at one-year of follow-up. Overall mortality rates 
at 30-day and one-year follow-up was assessed 
in the comparison between TAVI vs. SAVR. We 
also evaluated the influence by the site access for 
TAVI performed through the femoral or subclavi-
an artery (TV-TAVI) vs. SAVR, or transapically 
(TA-TAVI) vs. SAVR. We performed intention to 
treat (ITT) and “as treated” analysis in the com-
parison between TAVI vs. SAVR. We choose “as 
treated analysis” in the comparisons of subgroups 
TV-TAVI vs. SAVR and TA-TAVI vs. SAVR, as 
suggested by the regulatory agencies, because the 
data are derived mainly from non-inferiority trial 
design (www.fda.gov/Drugs/GuidanceCompli-
anceRegulatoryInformation/Guidances/default.
htm). Bidirectional α error <0.05 was considered 
as statistically significant.
Results
Of 6,089 studies identified for screening, af-
ter detailed review, 8 RCTs and 14 related arti-
cles meet the inclusion criteria and were select-
ed4,5,7,12,13,26-34. The selected RCTs included 8,090 
patients initially randomized to TAVI or SAVR. 
PRISMA flow diagram for the study selection 
process is reported in the Figure 1. Out of 8 
RCTs, 6 were designed to compare the non-in-
feriority of TAVI vs. SAVR and includes 7,740 
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randomized patients, 2 were designed to compare 
the superiority of TAVI vs. SAVR in 350 patients 
randomized to treatments (Table I). The char-
acteristics of the RCTs included are reported in 
Table I-II. ITT or “as treated” analysis was not 
performed in all the comparisons due to missing 
data (Table II). Indeed PARTNER 334, report 
only results for “as treated” patients while, for 
SURTAVI trial12, only modified ITT data were 
available. We found no significant difference on 
30-day mortality between TAVI vs. SAVR in 
ITT analysis (RD: -0.00; 95% CI from -0.01 to 
0.00; p=0.45). In “as treated” population 30-day 
mortality was significantly lower for TAVI com-
pared to SAVR (RD: -0.01, 95% CI from -0.02 to 
-0.00, p=0.03) (Figure 2). When we analyzed TA-
VI subgroups, a significant reduction in 30-day 
mortality was observed in TV-TAVI vs. SAVR 
(RD: -0.01; 95% CI from -0.02 to -0.00; p=0.006). 
Increased, not significantly, 30-day mortality was 
observed in TA-TAVI compared to SAVR, (RD: 
0.02; 95% CI from -0.04 to 0.08; p=0.62) (Figure 
3). The trials included had homogeneous data into 
each subgroup (I2=6% in TV-TAVI and I2=0% 
in TA-TAVI) (Figure 3). The results at one-year 
follow-up showed that in the comparison between 
TAVI vs. SAVR, there was a non-significant 2% 
absolute risk reduction (RD: -0.02; 95% CI from 
-0.04 to 0.00; p=0.06). No significant differences 
were also found in the comparison between TAVI 
subgroups vs. SAVR (Figure 4). 
Discussion
TAVI is considered equal or even superior to 
SAVR regarding early mortality when TF ac-
cess is used35. TF-TAVI seems to be associated 
Figure 1. Flowchart of the study selection process. RCTs: Randomized controlled trials.
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Figure 2. 30-day mortality in overall TAVI population of patients. A, ITT; B, “as treated”. ITT: intention to treat.
Figure 3. 30-day mortality in TAVI “as treated” subgroups population. 
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with significantly higher early and intermediate 
survival compared with TA-TAVR36. TA-TAVI, 
widely used in the past, is nowadays considered 
inferior to TF-TAVI37-40 and its role is at a turning 
point. The PARTNER trial investigators demon-
strated the negative impact of TA-TAVI on two-
year all-cause mortality in patients with and with-
out left ventricular dysfunction41. The PARTNER 
3 trial investigators reported that in patients with 
severe aortic stenosis who were at low-surgical 
risk, the rate of the composite of death, stroke, or 
re-hospitalization at 1 year was significantly low-
er with TAVI than with SAVR34. Indeed the EVO-
LUT LOW RISK trial investigators showed that 
in patients with severe AS who were at low sur-
gical risk, TAVI with a self-expanding supra-an-
nular bioprosthesis was non-inferior to SAVR 
with respect to the composite end point of death 
or disabling stroke at 24 months33. However, re-
cent registries have shown conflicting results on 
post-operative mortality when the access sites for 
TAVI entered the analysis41. Furthermore, a re-
cent contemporary large study on utilization and 
outcomes of TF vs. TA-TAVI in real-world patient 
populations, showed that TF approach should be 
preferred over a TA approach for TAVI whenever 
possible42,43. In adjunct the analysis of data from 
UK TAVI registry showed that TA and DA-TA-
VI were associated with similar survival, both 
significantly worse than with the TF route38,44. 
Figure 4. One-year mortality in TAVI “as treated” population. A, Overall population. B, Subgroups of patients.
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Moreover, TS access for TAVI provide result sim-
ilar to TF-TAVI and may represent the safest non 
femoral access route37,38. However, data from ob-
servational studies could overestimate the treat-
ments effect due to the lack of randomization45,46. 
On the contrary, RCTs are considered a key tool 
for comparative effectiveness research, because, 
through randomization: (1) patients are assigned 
to experimental or control group by chance in 
order to reduce errors or bias and (2) only the real 
differences due to the treatment are remarked47,48. 
Based on these observations, we have chosen to 
perform a meta-analysis on the available RCTs in 
order to examine the impact of TAVI and SAVR 
on death from any cause at 30-day and at one-
year of follow-up in patients with AS at high and 
low-intermediate surgical risk (Figure 2, 4). In 
the meta-analysis we also assessed the role played 
by the site access for TAVI (Figure 3, 4). As 
confirmation of the actuality of the TV approach 
for TAVI, the majority of the patients included 
in the meta-analysis (93.4%) belonged to the 
TV-TAVI subgroup and a lower number (6.6%) 
to the TA-TAVI subgroup (Figure 3). We did not 
found significant differences between TAVI vs. 
SAVR at 30-day (ITT population) and one-year 
mortality (Figure 2, 4). The estimate is the result 
of two opposite trends: a significant reduction 
in mortality in TV-TAVI compared to SAVR 
(p=0.006) and an increased mortality, although 
not significant, in TA-TAVI compared to SAVR 
(p=0.62) (Figure 3). The results demonstrate that 
the analysis performed without outlining the im-
portance of take into account the arterial access 
site for TAVI can be confusing and lead to biased 
results49. Again, our findings are in agreement 
with those of the STACCATO trial27, which, de-
signed to investigate the superiority of TA-TAVI 
compared to SAVR, showed a negative effect of 
TA-TAVI with respect to SAVR. In fact, the trial, 
designed to enroll 200 patients, was interrupted 
prematurely after enrolling only 70 patients, due 
to an excess of adverse events in the TA-TAVI 
group. Finally the significant beneficial impact 
on the 30-day mortality of TV-TAVI can be at-
tributable to its non-invasive nature, with respect 
to TA-TAVI and SAVR41, that are full-fledged 
surgical procedures and as such imply a different 
postoperative course43. The choice to include in 
the meta-analysis only the RCTs to avoid bias, 
does not exclude the limitation of the insufficient 
number of patients enrolled. In addition, we 
could not perform the analysis of data with both 
ITT and “as treated” approach due to the lack of 
details related to the TAVI subgroups (Table II). 
Indeed, in SURTAVI12 only the analysis for ITT 
patient population and in PARTNER 334 only “as 
treated” analysis were performed.
Conclusions
Our meta-analysis show the lack of significant 
differences on the incidence of 30-day and one-
year mortality of TAVI vs. SAVR in the overall 
data analysis. However, the analysis can lead to 
misleading results when the comparisons are 
performed without taking into account the sub-
groups selected on the basis of the arterial access 
site for TAVI. Indeed, in the analysis of TAVI 
subgroups, our data suggest the significant supe-
riority of TV-TAVI vs. SAVR in terms of 30-day 
mortality reduction, irrespective of surgical risk 
category. Finally, TA-TAVI was affected by high-
er, not significant, occurrence of 30-day mortality 
compared to SAVR.
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